Today in Banking
SEE OTHER BRANDS

Reporting on banking news in the world

Today in Banking: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Banking.

Press releases published on June 2, 2025

Regency Centers Receives Green Lease Leaders Platinum Recognition for Sustainability

Regency Centers Receives Green Lease Leaders Platinum Recognition for Sustainability

JACKSONVILLE, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency”, “Regency Centers” or the “Company”) (Nasdaq:REG) is pleased to announce that it has been included as a 2025 Green Lease Leader with Platinum recognition, as …

Plexus Issues Fiscal 2024 Sustainability Report

Plexus Issues Fiscal 2024 Sustainability Report

NEENAH, Wis., June 02, 2025 (GLOBE NEWSWIRE) -- Plexus Corp. (NASDAQ: PLXS) today released its fiscal 2024 Sustainability Report. The report, which is now available on the company’s Sustainability web page, highlights how Plexus’ commitment to …

Bitget Lists LABUBU (LABUBU) in the Innovation and Meme Zone

Bitget Lists LABUBU (LABUBU) in the Innovation and Meme Zone

Victoria, Seychelles, June 2nd, 2025, Chainwire Bitget, the leading cryptocurrency exchange and Web3 company, has announced the listing of LABUBU (LABUBU) in its Innovation and Meme Zone. Trading for the LABUBU/USDT pair commenced on May 30, 2025, at 14:00 …

Alpha Modus Holdings, Inc. CEO Affiliates To Exchange Preferred Stock for Common Stock, Demonstrating Confidence in Near Future Outlook

Alpha Modus Holdings, Inc. CEO Affiliates To Exchange Preferred Stock for Common Stock, Demonstrating Confidence in Near Future Outlook

CORNELIUS, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD), a pioneer in AI-driven retail technology, today announced that CEO William Alessi’s affiliated family trusts have agreed to voluntarily exchange a substantial …

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE …

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, …

Joint Press Release of Constellation Software Inc. and Topicus.com Inc. -- Topicus.com Inc. completes acquisition of Cipal Schaubroeck in Belgium

Joint Press Release of Constellation Software Inc. and Topicus.com Inc. -- Topicus.com Inc. completes acquisition of Cipal Schaubroeck in Belgium

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus’ subsidiary Total Specific Solutions (TSS) B.V. (“TSS”) has completed the sale and transfer of all issued and …

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly …

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines …

Liberty Defense Commences Normal Course Issuer Bid to Buy Back Up-to 9.9% of the Publically Traded Float

Liberty Defense Commences Normal Course Issuer Bid to Buy Back Up-to 9.9% of the Publically Traded Float

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. WILMINGTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN, OTCQB: LDDFF, FSE: E30), a leading …

CAPREIT to Invest in Canadian Housing Supply with Construction of 170 Residential Suites Within Existing Portfolio

CAPREIT to Invest in Canadian Housing Supply with Construction of 170 Residential Suites Within Existing Portfolio

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today that it is planning to invest in two infill development projects for the construction of an estimated 120 …

Trust Wallet Launches Buy+, Powered by Binance Connect, to Simplify Crypto Access

Trust Wallet Launches Buy+, Powered by Binance Connect, to Simplify Crypto Access

  Users can buy tokens on BNB Chain, Base and Solana directly with cards, local currency and more - all without leaving the Trust Wallet app. DUBAI, United Arab Emirates, June 02, 2025 (GLOBE NEWSWIRE) -- Trust Wallet, the world’s leading self-custody Web3 …

COS Systems expands Open Access Services partnership with Fujitsu

COS Systems expands Open Access Services partnership with Fujitsu

Extended partnership enables turn-key Open Access network operations backed by COS Business Engine. WEST PALM BEACH, FL, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- COS Systems continues to strengthen its partnership with Fujitsu, a leading …

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25 …

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average …

  STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of Common Share Repurchase Program Disclosure of Transactions in Own Shares – Period from May 26, 2025 to May 30, 2025 AMSTERDAM – June 2, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global …

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE …

Xunlei Closes Acquisition of Hupu

Xunlei Closes Acquisition of Hupu

SHENZHEN, China, June 02, 2025 (GLOBE NEWSWIRE) -- Xunlei Limited ("Xunlei" or the "Company") (Nasdaq: XNET), a leading technology company providing distributed cloud services in China, today announced that it has closed the acquisition of Shanghai …

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 …

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service